Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China.
Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China.
复制标题
DOI：
10.1093/jac/dkm175
复制
发表时间：
2007-08
期刊：
影响因子：
--
通讯作者：
G. Yao
中科院分区：
文献类型：
--
作者：
G. Yao
乙型肝炎病毒 (HBV) 感染可导致许多患者患上慢性乙型肝炎 (CHB)。慢性乙型肝炎患者需要定期筛查和监测，以促进疾病监测并确定是否/何时需要治疗。目前慢性乙型肝炎治疗的目标是持续抑制病毒，以减少或预防肝损伤和疾病进展。现在已有有效的抗乙型肝炎疗法，可以抑制但不能根除乙型肝炎病毒复制。在目前获得许可和批准的抗乙肝病毒核苷类药物中，恩替卡韦具有强效的抗乙肝病毒活性，且耐药发生率低，具有良好的安全性和耐受性。这些优异的药理学特性在大型国际临床试验和中国的单独研究中得到了评估。本文介绍了涉及 876 名中国慢性乙型肝炎患者的 II 期和 III 期试验的结果。这些研究结果表明，恩替卡韦应被推荐为目前可用的抗乙型肝炎核苷类药物中的一线选择。
Infection with the hepatitis B virus (HBV) can result in chronic hepatitis B (CHB) in many patients. Patients with CHB require regular screening and monitoring to facilitate disease surveillance and to determine if/when treatment is indicated. The current goal of CHB treatment is sustained viral suppression with the aim of reducing or preventing hepatic injury and disease progression. Effective anti-HBV therapy is now available that can suppress, but not eradicate, HBV replication. Among the currently licensed and approved anti-HBV nucleos(t)ides, entecavir demonstrates a potent anti-HBV activity and a low rate of emergence of drug resistance, with good safety and tolerability profiles. These excellent pharmacological characteristics were assessed both in large international clinical trials and in separate studies in China. This article presents results from Phase II and Phase III trials involving 876 Chinese patients with CHB. The results of these studies suggest that entecavir should be recommended as a first-line choice among the currently available anti-HBV nucleos(t)ides.